Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. addition

ADDITION

Arthritis Differential DIagnostic validaTION

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ADDITION project word cloud

Explore the words cloud of the ADDITION project. It provides you a very rough idea of what is the project "ADDITION" about.

economic    turnover    eular2010    adequacy    therapeutic    arthritis    40    inappropriate    larger    rheumakit    predict    web    socio    tool    validated    clinically    clinical    genes    describes    procedure    signature    leads    unsatisfactory    provides    subclass    incidence    feasibility    90    lab    marked    few    functional    kit    market    rheumatoid    280m    spondylarthropaties    seronegative    complemented    validate    1000    probabilities    treatment    progression    collection    suffering    pcr    impacts    newly    osteoarthritis    consists    accuracy    ua    2014    diseases    health    diagnostic    differential    methotrexate    vs    mtx    trancriptomic    serious    efficacy    treatments    distinction    criterion    prospective    techniques    synovial    involve    patient    clinicians    annual    huge    ra    solution    expenses    patients    limited    logistics    transportation    cloud    cohort    unjustified    line    earlier    biopsy    central    joints    ea    diagnosed    140m    infrastructure    ineffective    first    computing    ce    500    ing    mistake    useless    acr    group    inflammation    strategies    undifferentiated   

Project "ADDITION" data sheet

The following table provides information about the project.

Coordinator		 DNALYTICS 

Organization address
address: CHEMIN DU CYCLOTRON 6
city: OTTIGNIES LOUVAIN LA NEUVE
postcode: 1348
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Belgium [BE]
 Project website http://www.dnalytics.com. The RheumaKit online platform
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2015-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DNALYTICS BE (OTTIGNIES LOUVAIN LA NEUVE) coordinator 50˙000.00

Map

 Project objective

Arthritis, a group of diseases involving inflammation of joints with huge health and socio-economic impacts. Early Arthritis (EA) describes newly diagnosed arthritis (incidence 2/1000). An improved arthritis management requires to enhance the EA differential diagnostic efficacy and the adequacy of the therapeutic strategies. The earlier arthritis is addressed, the more likely its progression will be limited. A mistake in differential diagnostic leads to inappropriate treatments, resulting in useless expenses and serious side effects, unjustified. Current diagnostic techniques are unsatisfactory and the most used first line treatment, Methotrexate (MTX), is ineffective in about 40% of the patients. RheumaKit is a solution for clinicians for the early differential diagnostic of patients suffering from undifferentiated arthritis (UA, a subclass of EA). RheumaKit is based on a trancriptomic signature of about 100 genes complemented by 3 clinical factors. It provides a 90% accuracy for the Rheumatoid Arthritis (RA) vs non-RA distinction, far above the ACR/EULAR2010 criterion on the same patients. It also provides probabilities for Osteoarthritis and Seronegative Spondylarthropaties. The solution consists of a synovial biopsy collection and transportation kit (CE-marked May 2014), a central lab PCR procedure, and a web application computing the effective diagnostic on a cloud-computing infrastructure. Functional, technical, logistics aspects of RheumaKit have been validated. ADDITION aims at clinically validate on a larger patient cohort the existing RheumaKit signature for the differential diagnostic of most EA patients and validate the use of the existing RheumaKit signature as a tool to predict MTX response. ADDITION phase 2 will involve a prospective study on 500 to 1000 EA patients. The main phase 1 objectives are a feasibility study of the clinical and market aspects of ADDITION. The expected annual turnover is above 140M€-280M€ in EU within a few years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADDITION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADDITION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More